BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shanghai HEP Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shanghai HEP Pharmaceutical's dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07309380-446@assetmemo.bio
DTSTAMP:20261121T005930Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:hepalatide: Phase 3 readout est. (NCT07309380)
DESCRIPTION:hepalatide\, phase 3.\nStudy: Phase III Clinical Trial of Hepal
 atide in Patients With Chronic Hepatitis D\nEstimated primary completion: 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hepalatide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 09380
URL:https://assetmemo.bio/drug/hepalatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
